World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
45146
World Ranking
14356
National Ranking
7259

Overview

Daniel P. Petrylak is affiliated with Yale School of Medicine in the United States. Their research is primarily focused within the field of Medicine, with significant contributions in Surgery, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

The scientist's main research topics cover several areas related to oncology and cancer treatment. These include:

  • Bladder and Urothelial Cancer Treatments
  • Cancer Immunotherapy and Biomarkers
  • Urinary and Genital Oncology Studies
  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Esophageal Cancer Research and Treatment
  • Peptidase Inhibition and Analysis

Research publications by Daniel P. Petrylak have appeared in several notable journals. The most frequent venues for publication are:

  • Journal of Clinical Oncology (100 publications)
  • Annals of Oncology (25 publications)
  • Clinical Cancer Research (9 publications)
  • European Urology (9 publications)
  • The Journal of Urology (8 publications)

Recent significant papers include the following:

  • "Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma," 2020, New England Journal of Medicine
  • "Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma," 2021, New England Journal of Medicine
  • "TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors," 2021, Journal of Clinical Oncology
  • "Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial," 2020, The Lancet Oncology
  • "Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial," 2021, The Lancet Oncology

Daniel P. Petrylak has collaborated extensively with several researchers. Frequent co-authors include:

  • Yohann Loriot (57 co-authored works)
  • Jonathan E. Rosenberg (53 co-authored works)
  • Petros Grivas (47 co-authored works)
  • Cora N. Sternberg (43 co-authored works)
  • Thomas Powles (40 co-authored works)

Best Publications

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

    Daniel P. Petrylak;Catherine M. Tangen;Maha H.A. Hussain;Primo N. Lara

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    Thomas Powles;Se Hoon Park;Eric Voog;Claudia Caserta

  • ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    Andrew J. Armstrong;Russell Z. Szmulewitz;Daniel P. Petrylak;Jeffrey Holzbeierlein

  • Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

    George L. Wright;George L. Wright;B. Mayer Grob;B. Mayer Grob;Cara Haley;Cara Haley;Katie Grossman;Katie Grossman

  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    Thomas Powles;Jonathan E Rosenberg;Guru P Sonpavde;Yohann Loriot

  • Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

    Jonathan E. Rosenberg;Jonathan E. Rosenberg;Peter H. O’Donnell;Arjun V. Balar;Bradley A. McGregor

  • Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    Maha H.A. Hussain;Gary R. MacVicar;Daniel P. Petrylak;Rodney L. Dunn

  • Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer

    Carlos Cordon-Cardo;David Wartinger;Daniel Petrylak;Guido Dalbagni

  • Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

    Josep Domingo-Domenech;Samuel J. Vidal;Veronica Rodriguez-Bravo;Mireia Castillo-Martin

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Susan Halabi;William Kevin Kelly;Hua Ma;Haojin Zhou

  • TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.

    Scott T Tagawa;Arjun V Balar;Daniel P Petrylak;Arash Rezazadeh Kalebasty

  • Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

    Daniel P. Petrylak;Robert B. Macarthur;John O'Connor;Gary Shelton

  • Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

    Nadeem Sheikh;Daniel Petrylak;Philip Wayne Kantoff;Corazon dela Rosa

  • A pilot study of the vulnerable elders survey‐13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation

    Supriya G. Mohile;Kathryn Bylow;William Dale;James Dignam

Frequent Co-Authors

Maha Hussain
Maha Hussain Northwestern University
Emilia Bagiella
Emilia Bagiella Icahn School of Medicine at Mount Sinai
Walter M. Stadler
Walter M. Stadler University of Chicago
Tomasz M. Beer
Tomasz M. Beer Oregon Health & Science University
E. David Crawford
E. David Crawford University of California, San Diego
Supriya G. Mohile
Supriya G. Mohile University of Rochester Medical Center
Mario A. Eisenberger
Mario A. Eisenberger Johns Hopkins University
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
David M. Nanus
David M. Nanus Cornell University
Cora N. Sternberg
Cora N. Sternberg Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA offers a range of educational options, many of which are now available online. For those considering alternative routes to traditional medical school, online nursing degrees can provide flexible and affordable pathways.

Becoming a nurse practitioner is a popular choice for those seeking advanced roles. Today, cheapest np programs online allow students to earn their qualification at a reduced cost without relocating or pausing their career. If you're aiming for a foundational nursing career, you may explore the cheapest bsn programs online, offering quality bachelor’s degrees recognized nationwide.

For registered nurses looking to advance their education, numerous what is the cheapest rn to bsn program online opportunities exist, making it easier to upgrade credentials and boost career prospects. Those seeking leadership or research roles might consider doctoral studies; exploring the cheapest dnp programs online can help minimize student debt while expanding professional options.

By carefully selecting accredited, affordable online programs, you can find a pathway that aligns with your career goals and budget.

Best Scientists Citing Daniel P. Petrylak

Trending Scientists

Recently Published Articles